Sentaur Bio is a biotech company with a focus on senescence biology that discovers and develops breakthrough treatments for debilitating age-related diseases.
Sentaur’s library of distinct senescent cell surface proteins discovered by high throughput proteomic analysis, was licensed from the laboratory of Prof. Valery Krizhanovsky, an Associate Professor at the Weizmann Institute of Science and a world-renowned expert in senescence. By leveraging its powerful library platform of distinct cell surface proteins, Sentaur’s mission is to treat diseases involving senescent cells burden, with primary focus in oncology and in the future debilitating age-related diseases.
The company also aims to leverage its platform to continue discovering and developing surface markers of senescence by strategic partnering.
